Budget impact analysis of ixabepilone used according to FDA-approved labeling in treatment-resistant metastatic breast cancer

Journal of Managed Care Pharmacy

Volumn 15, Issue 6, 2009, Pages 467-475

  Ho, Joanne ^a   Zhang, Lihua ^b   Todorova, Lora ^c   Whillans, Finlay ^d   Corey Lisle, Patricia ^b   Yuan, Yong ^b  

^a Dymaxium Inc   (Canada)

^b BRISTOL MYERS SQUIBB   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Wyeth Pharmaceuticals   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPOTHILONE A; FLUOROURACIL; GEMCITABINE; IRINOTECAN; IXABEPILONE; METHOTREXATE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; BUDGET; DRUG COST; DRUG INDICATION; DRUG LABELING; DRUG MARKETING; DRUG UTILIZATION; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PLANNING; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MONOTHERAPY; PRACTICE GUIDELINE; PROGNOSIS; REIMBURSEMENT; SENSITIVITY ANALYSIS;

EID: 69149106494     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2009.15.6.467     Document Type: Article

References (38)

1. American Cancer Society. Cancer Facts and Figures 2009. Available at: http://www.cancer.org/downloads/STT/500809web.pdf. Accessed July 10, 2009.
2. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996,14(8):2197-2205
3. Cardoso F, Di LA, Lohrisch C, Bernard C, Ferreira F, Piccart MJ. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol. 2002;13(2):197-207.
4. Chia SK, Speers CH, D'yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110(5):973-979
5. Takeda AL, Jones J, Loveman E, Tan SC, Clegg AJ. The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation. Health Technol Assess. 2007;ll(19):iii,ix-xi,l-62.
6. Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998;339(14): 974-984
7. O'Shaughnessy J, Twelves C, Aapro M. Treatment for anthracycline-pre- treated metastatic breast cancer. Oncologist. 2002;7(Suppl 6):4-12. (Pubitemid 36008991)
8. Vahdat LT, Thomas E., Li R., et al. Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes. Poster presented at: 2007 American Society of Clinical Oncology Annual Meeting; June 1-5, 2007; Chicago, IL.
9. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733-43. Available at: http://content.nejm.org/cgi/reprint/355/26/2733.pdf. Accessed July 9, 2009. (Pubitemid 46021510)
10. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23(4):792-799 (Pubitemid 46224178)
11. Holfe G RH. Epothilone, a myxobacterial metabolite with promising antitumor activity. In: Cragg GM, Kingston DGI, Newman DJ, eds. Anticancer Agents From Natural Products. Boca Raton, London: Taylor and Francis Group; 2005:413-450
12. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001;7(5):1429-1437 (Pubitemid 32708699)
13. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.J Clin Oncol. 2007;25(23):3407-3414
14. Vahdat L. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Oncologist. 2008;13(3):214-221 (Pubitemid 351679896)
15. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25(33):5210-17. Available at: http://jco.ascopubs. org/cgi/reprint/25/33/5210. Accessed July 15, 2009.
16. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices-budget impact analysis. Value Health. 2007;10(5):336-347 (Pubitemid 47481105)
17. Surveillance, Epidemiology, and End Results (SEER) Program Table 1-22. U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2005 By Age At Prevalence. Cancer Statistics Branch. Available at: http://seer.cancer.gov/ csr/1975-2005/results-single/sect-01-table.22-2pgs.pdf.Accessed July 9, 2009.
18. CancerMpact. Comprehensive Cancer Epidemiology Database: 2008. Proprietary and nonpublished data; available for purchase at: http://www.mattsonjack.com/patient-metrics.asp. Accessed July 9, 2009.
19. IntrinsiQ. Research Market Share Data: 2007. Proprietary and nonpublished data, available for purchase at: http://www.intrinsiq com/index.aspx. Accessed July 9, 2009.
20. Wholesale Acquisition Cost (March 2009). First DataBank Inc. Available for purchase at: www.firstdatabank.com/products/price-point-rx/. Initially accessed March 2009. Last accessed July 9, 2009.
21. U.S. Food and Drug Administration. Approved label for Avastin (bevacizumab). Available at: http://www accessdata.fda.gov/drugsatfda-docs/ label/2009/125085s01691bl.pdf. Accessed July 6, 2009.
22. Rheumatrex (methotrexate) Product Information. Stada Pharmaceuticals Inc. Available at: http://www.rheumatrex.info/pdf/RheumatrexPackageInsert. pdf. Accessed July 6, 2009.
23. U.S. Food and Drug Administration. Approved label for Camptosar irinotecan. Available at: http://www accessdata.fda.gov/drugsatfda-docs/ label/2006/020571s0301bl.pdf. Accessed July 6, 2009.
24. U.S. Food and Drug Administration. Approved label for Herceptin (trastuzumab). Available at: http://www.accessdata.fda.gov/drugsatfda-docs/ label/2008/103792s51751bl.pdf. Accessed July 6, 2009.
25. U.S. Food and Drug Administration. Approved label for Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2008/021660s0131bl.pdf. Accessed July 6, 2009.
26. U.S. Food and Drug Administration. Approved label for Gemzar (gemcitabine HCl). Available at: http://www accessdata.fda.gov/drugsatfda-docs/label/2005/ 020509s0331bl.pdf. Accessed July 6, 2009.
27. U.S. Food and Drug Administration. Approved label for Taxotere (docetaxel). Available at: http.//www accessdata.fda.gov/drugsatfda-docs/ label/2007/020449s0451bl.pdf. Accessed July 6, 2009.
28. U.S. Food and Drug Administration. Approved label for Xeloda (capecitabine). Available at: http://www.accessdata.fda.gov/drugsatfda-docs/ label/2005/020896s0161bl.pdf. Accessed July 6, 2009.
29. Fluorouracil (Fluorouracil Injection, USP) Product Information. Parenta pharmaceuticals. Available at: http://www.parentarx.com/files/prodfiles/ Approved-5FU-P106.30.09.pdf. Accessed July 6, 2009.
30. U.S. Food and Drug Administration. Approved label for Doxorubicin Hydrochloride. Available at: http://www accessdata.fda.gov/drugsatfda-docs/ label/2003/050467s0681bl.pdf. Accessed July 6, 2009.
31. Cytoxan (cyclophosphamide for injection, USP) Product Information. Bristol-Myers Squibb Company. Available at: http://packageinserts.bms.com/ pi/pi-cytoxan.pdf. Accessed July 6, 2009.
32. U.S. Food and Drug Administration. Approved label for Paraplatin (carboplatin aqueous solution) Injection. Available at: http://www.access-data. fda.gov/drugsatfda-docs/label/2004/20452scs001-paraplatin-lbl.pdf. Accessed July 6, 2009.
33. U.S. Food and Drug Administration. Approved label for Taxol (paclitaxel) Injection. Available at: http.//www.accessdata.fda.gov/drugsatfda-docs/label/ 2000/20262S36LBL.PDF. Accessed July 6, 2009.
34. U.S. Food and Drug Administration. Approved label for Ixempra Ku (ixabepilone) for Injection, Available at: http.//www accessdata.fda.gov/drug- satfda-docs/label/2009/022065s0011bl.pdf. Accessed July 6, 2009.
35. U.S. Food and Drug Administration. Approved label for Vinorelbine Injection USP. Available at: http://www.bedfordlabs com/BedfordLabsWeb/products/ inserts/VRLB-POl.pdf. Accessed July 11, 2009.
36. Curtiss FR. Pharmacy benefit spending on oral chemotherapy drugs. J Manag Care Pharm. 2006;12(7):570-577 Available at: http://amcp.org/data/jmcp/ contemporary-subjects-570-577.pdf.
37. Danese MD, Reyes C, Northridge K, Lubeck D, Lin CY, O'Connor P. Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer. Clin Ther. 2008;30(4):775-784 (Pubitemid 351689042)
38. Chang J, Sung J. Health plan budget impact analysis for pimecrolimus. J Manag Care Pharm. 2005;ll(l):66-73. Available at: http://www.amcp.org/ data/jmcp/Form-Manag-66-73 pdf.